The European Investment Bank (EIB) is giving a big financial boost to Italian drugmaker Alfasigma, promising €150 million to help push new medicines from the lab to the people who need them most. The loan, announced this week, will support Alfasigma’s research from 2025 to 2027, focusing on hard-to-treat rare diseases and specialty care—especially in digestive, liver, blood vessel, and joint conditions.
Alfasigma is already selling medicines in over 100 countries, but this funding is meant to help them take on even bigger challenges. Many people living with rare diseases don’t have good treatment options, so there’s a real need for new solutions that make a difference in their daily lives.
EIB Vice-President Gelsomina Vigliotti says this move shows just how committed the bank is to helping science and health innovation in Europe.
“Research and new ideas keep Europe competitive and help create jobs—and, most importantly, give new hope to patients,” she said.
Tatiana Simonelli, Alfasigma’s Chief Financial Officer, is eager for the partnership. She believes the loan will help the company grow faster and bring fresh treatments to market. “It means we can move quicker for patients dealing with tough, neglected conditions,” Simonelli explained.
With this collaboration, both EIB and Alfasigma are betting on smart ideas and teamwork to turn scientific advances into real change for patients in Europe and around the world.
